TOPLINE:
- An associate research study of medical care clients with weight problems discovered considerable associations in between weight management treatments (WMTs) and ≥ 5% weight-loss for people.
- Low WMT usage prevented population-level advantage.
APPROACH:
This retrospective, population-based cross-sectional friend research study consisted of 149,959 medical care clients from a Michigan scholastic health system in between October 2015 and March 2020.
TAKEAWAY:
- From 2017 to 2019, the typical unadjusted body mass index (BMI) increased from 29.34 kg/m2 to 29.61 kg/m2 and the frequency of weight problems from 39.2% to 40.7%.
- Amongst 31,284 clients with weight problems in 2017, 25.9% (6665) accomplished ≥ 5% weight reduction at 2 years.
- Amongst 37,245 with weight problems in either 2017 or 2019 and adequate follow-up, 1-year WMT usage increased from 5.3% in 2017 to 7.1% in 2019 (distinction, 1.7%; 95% CI, 1.3%-2.2%), consisting of dietary therapy (6.3%), weight-loss medication prescriptions (2.6%), and bariatric surgical treatment (1.0%).
- In 2 groups of n = 5090 with and without WMT direct exposure who were tendency rating– matched on covariates consisting of BMI, sex, and age, the likelihoods of ≥ 5% weight reduction at 1 year were 15.6% without WMTs, 23.1% for nutrition therapy, 54.6% for meal replacement, 27.8% for weight-loss medication, and 93% for bariatric surgical treatment, with all techniques substantial compared to no WMTs.
IN PRACTICE:
“Health systems and insurance providers must think about unique techniques to improve preference-sensitive usage of WMT to enhance accomplishment of 5% or higher weight reduction amongst people and populations with weight problems.”
“While we consisted of glucagon-like peptide 1 receptor agonists for type 2 diabetes, consisting of semaglutide 1.0 mg, in our analyses, the research study duration preceded the [US Food and Drug Administration]-approval of semaglutide 2.4 mg for weight management. Future work ought to check out the capacity for semaglutide 2.4 mg and other medications with significant weight-loss efficiency to decrease weight at the population level.”
SOURCE:
This research study was performed by James Henderson, PhD, of the Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, and coworkers and was released online on February 14, 2024, in JAMA Network Open
CONSTRAINTS:
Single health system. Electronic health record information might undergo weight and WMT measurement mistake, absence of adherence information, and any info about outdoors WMT gain access to. Retrospective, observational research study, based on predisposition. Research study duration took place before FDA approval of semaglutide for weight management, and therefore, the findings might downplay present usage and efficiency of weight-loss medications.
DISCLOSURES:
The research study was supported by grants from the National Institutes of Health and National Institute of Diabetes and Digestive and Kidney Diseases, Michigan Center for Diabetes Translational Research, Michigan Nutrition Obesity Research Center, and the Elizabeth Weiser Caswell Diabetes Institute at the University of Michigan. Henderson had no additional disclosures, however a few of the coauthors had market ties.
Miriam E. Tucker is a self-employed reporter based in the Washington, DC, location. She is a routine factor to Medscape Medical News,
